Sugi Predict

Sugi Predict / Compounds / SCHEMBL16925558

SCHEMBL16925558

SCHEMBL16925558

Cc1cc(I)cc(C(=O)O)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TPMT P51580 5/20 0.70
▸ HCAR1 Q9BXC0 1/20 0.59
▸ HCAR2 Q8TDS4 1/20 0.47
▸ RXRA P19793 1/20 0.45
▸ RXRB P28702 1/20 0.45
▸ ALDH1A1 P00352 2/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ CNR2 P34972 1/20 0.43
▸ CA12 O43570 2/20 0.41
▸ CA1 P00915 2/20 0.41
▸ CA2 P00918 2/20 0.41
▸ CA7 P43166 2/20 0.41
▸ CA9 Q16790 2/20 0.41
▸ CA14 Q9ULX7 2/20 0.41
▸ SRD5A2 P31213 1/20 0.40
▸ NOTUM Q6P988 1/20 0.40
▸ NR4A1 P22736 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL422824 0.83 TPMT (0.59) TPMTHCAR1ALDH1A1SMN1; SMN2CA12
SCHEMBL40661 0.83 TPMT (0.89) TPMTHCAR1HCAR2RXRARXRB
SCHEMBL1951073 0.83 TPMT (0.59) TPMTHCAR1ALDH1A1SMN1; SMN2CA12
SCHEMBL221684 0.83 TPMT (1.00) TPMTHCAR1HCAR2RXRARXRB
SCHEMBL6918090 0.80 TPMT (0.94) TPMTHCAR1HCAR2RXRARXRB
SCHEMBL6916035 0.80 TPMT (0.94) TPMTHCAR1HCAR2RXRARXRB
SCHEMBL6918621 0.80 TPMT (0.94) TPMTHCAR1HCAR2RXRARXRB
Hydrochloric Acid SCHEMBL9622124 0.80 TPMT (0.84) TPMTHCAR1HCAR2RXRARXRB
SCHEMBL6914123 0.80 TPMT (0.94) TPMTHCAR1HCAR2RXRARXRB
SCHEMBL6918093 0.80 TPMT (0.94) TPMTHCAR1HCAR2RXRARXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 — — US disclosed
EP-3856178-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-03-11 — — EP disclosed
CN-115335378-B Monoacylglycerol lipase modulators 詹森药业有限公司 2025-03-04 — — CN disclosed
EP-3584239-B1 O-AMINOHETEROARYL ALKYNYL-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF SHANGHAI INST MATERIA MEDICA CAS (CN) 2024-09-11 — — EP disclosed
CN-113164459-B Monoacylglycerol lipase modulators 詹森药业有限公司 2024-09-03 — — CN disclosed
US-20240228484-A1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-07-11 — — US disclosed
US-20240228484-A1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-07-11 — — US disclosed
US-12018007-B2 Method for manufacturing diarylmethane compound TOKUYAMA CORPORATION (JP) 2024-06-25 — — US disclosed
US-11891387-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2024-02-06 — — US disclosed
US-11820766-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-11-21 — — US disclosed
EP-3148979-B1 PROCESS FOR PREPARATION OF CANAGLIFLOZIN GLENMARK PHARMACEUTICALS LTD (IN) 2019-02-06 — — EP disclosed
US-9957231-B2 Iodine(II)-mediated radiofluorination THE GENERAL HOSPITAL CORPORATION (US) 2018-05-01 — — US disclosed
US-20170351177-A1 RESIST COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2017-12-07 — — US disclosed
US-9695159-B2 Process for preparation of canagliflozin GLENMARK PHARMACEUTICALS LIMITED (IN) 2017-07-04 — — US disclosed
US-20170114051-A1 PROCESS FOR PREPARATION OF CANAGLIFLOZIN GLENMARK LIFE SCIENCES LIMITED (IN) 2017-04-27 — — US disclosed
EP-3148979-A1 PROCESS FOR PREPARATION OF CANAGLIFLOZIN Glenmark Pharmaceuticals Limited (IN) 2017-04-05 — — EP disclosed
WO-2015181692-A1 PROCESS FOR PREPARATION OF CANAGLIFLOZIN GLENMARK PHARMACEUTICALS LIMITED (IN) 2015-12-03 — — WO disclosed
WO-2015109130-A1 AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS NOVIRA THERAPEUTICS, INC. (US) 2015-07-23 — — WO disclosed
CN-1732154-B Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM PHARMA 2010-09-08 — — CN disclosed
CN-1732154-A Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM PHARMA (DE) 2006-02-08 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018007-B2 Method for manufacturing diarylmethane compound GLP1R, IAPP, ARRB1 TPMT 855/4885HCAR1 1803/4885HCAR2 1678/4885
US-20240228484-A1 MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP TPMT 3400/4885HCAR1 1924/4885HCAR2 1948/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH TPMT 2435/4885HCAR1 878/4885HCAR2 702/4885
US-11891387-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP TPMT 3400/4885HCAR1 1924/4885HCAR2 1948/4885
US-20170351177-A1 RESIST COMPOSITION AND PATTERNING PROCESS INSR, EWSR1, INSRR TPMT 3966/4885HCAR1 879/4885HCAR2 1032/4885
US-20170114051-A1 PROCESS FOR PREPARATION OF CANAGLIFLOZIN SLC5A2, SLC5A1, SLC2A4 TPMT 948/4885HCAR1 1369/4885HCAR2 1015/4885
US-11820766-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP TPMT 4042/4885HCAR1 1471/4885HCAR2 1119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.